Key result
Intermediate global cardiovascular risk markers assessed early in clinical trials could identify harmful or neutral off-target drug effects before full trial completion.
Answers are grounded in this paper and cite their sources.
This editorial advocates for incorporating reproducible intermediate global cardiovascular risk markers (such as endothelial function) early into clinical trial designs to detect net off-target harms and guide early termination decisions.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Joseph Yeboah (2011) conducted an editorial in Cardiovascular disease risk. Intermediate global cardiovascular risk markers was evaluated. Intermediate global cardiovascular risk markers assessed early in clinical trials could identify harmful or neutral off-target drug effects before full trial completion.
Synapse has enriched 10 related papers. Consider them for comparative context: